Quorum-Sensing Molecule Modifies Gut Microbiota

Increasing the abundance of a chemical some microbes use to communicate with one another can help reinstate beneficial bacterial populations in the guts of antibiotic-treated mice.

Written byAnna Azvolinsky
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Macrocolony of two E. coli strains that either produce or scavange AI-2OZ OZKAYA, INSTITUTO GULBENKIAN DE CIENCIAA bacterial signaling molecule can alter the composition of the gut microbiome in mice, according to the results of a study published today (March 19) in Cell Reports. Researchers from the Instituto Gulbenkian de Ciencia (IGC) in Oeiras, Portugal, have shown that boosting the levels of a quorum-sensing molecule in the intestines of mice treated with a gut microbe-depleting antibiotic results in the repopulation of beneficial bacterial species.

This quorum-sensing molecule, made and sensed by some microbes, is used by individual bacterium to sense the presence of other bacteria in their environment. The IGC team’s results point to a potential way to manipulate this molecule, called pan-species autoinducer-2 (AI-2), to promote healthy gut microbiota following diet- and disease-related perturbations.

“While the vast majority of studies on the microbiome identify different bacteria present in the gastrointestinal tract, what is different and important about [this] approach . . . is in trying to manipulate the signaling in the GI tract,” said William Bentley, a bioengineer at the University of Maryland.

“It’s a proof of principle that we can increase the fitness of specific microbial groups in the gut,” said Marvin Whiteley, a microbiologist at the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • head shot of blond woman wearing glasses

    Anna Azvolinsky received a PhD in molecular biology in November 2008 from Princeton University. Her graduate research focused on a genome-wide analyses of genomic integrity and DNA replication. She did a one-year post-doctoral fellowship at Memorial Sloan Kettering Cancer Center in New York City and then left academia to pursue science writing. She has been a freelance science writer since 2012, based in New York City.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies